Depression can be overwhelming

Help relieve the symptoms of depression

FETZIMA® is FDA-approved for the treatment of Major Depressive Disorder (MDD) in adults.

  • Impact on
    Depressive Symptoms

    See how FETZIMA patients achieved significant improvement in depressive symptoms across 3 dosage strengths.1-4

    See MADRS Results >
  • Impact on
    Functional Impairment

    See how FETZIMA leads to significant improvement in functional impairment in patients with MDD. 1-4

    See SDS Results >
  • FETZIMA
    Savings

    Your eligible patients may pay as little as $20 (save up to $80) for each of their next 12 prescriptions. Restrictions apply.

    View Offers >
 

FETZIMA INDICATION AND USAGE

  • FETZIMA (levomilnacipran extended-release capsules) is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults.
  • FETZIMA is not approved for the management of fibromyalgia, and its efficacy and safety have not been established for that use.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older.
In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.
FETZIMA is not approved for use in pediatric patients.

Contraindications

Warnings and Precautions
Adverse Reactions

The most commonly observed adverse reactions in MDD patients treated with FETZIMA in placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea (17% vs 6%), constipation (9% vs 3%), hyperhidrosis (9% vs 2%), heart rate increased (6% vs 1%), erectile dysfunction (6% vs 1%), tachycardia (6% vs 2%), vomiting (5% vs 1%), and palpitations (5% vs 1%).

Please also see the full Prescribing Information.


IMPORTANT SAFETY INFORMATION
See More